SWOG 0709: Randomized Phase II Trial of Erlotinib vs. Erlotinib plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay

BACKGROUND: Advanced stage non-small cell lung cancer (NSCLC) patients with borderline performance status (PS2) are often excluded from clinical trials and platinum-based therapy. In light of the potential role for serum proteomics in predicting erlotinib benefit beyond that of EGFR mutational statu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Principais autores: Lara, Primo N., Moon, James, Hesketh, Paul J., Redman, Mary W., Williamson, Stephen K., Akerley, Wallace L., Hirsch, Fred R., Mack, Philip C., Gandara, David R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775366/
https://ncbi.nlm.nih.gov/pubmed/26725184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2015.11.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados